The biotech firm maintains its 2026 revenue guidance while announcing a share repurchase program exceeding $200M.
ADMA Biologics confirmed its Q2 2026 revenue guidance of $530M to $560M during an earnings call, citing accelerating demand for its higher-margin immunoglobulin product, ASCENIV. The company reported the strongest sequential utilization growth in June since launch, reinforcing confidence in its outlook.
The guidance aligns with prior projections, reflecting steady performance in the immunoglobulin market. ADMA also announced plans to repurchase over $200M in shares, signaling management’s optimism about future cash flow and valuation.
No immediate market reaction was disclosed, but the buyback program may support investor sentiment amid ongoing demand growth for its core product.